<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medications for cholestatic pruritus in Alagille syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medications for cholestatic pruritus in Alagille syndrome</h1>
<div class="graphic"><div class="figure"><div class="ttl">Medications for cholestatic pruritus in Alagille syndrome</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="15%"></colgroup><colgroup span="2" width="35%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Category</td> <td class="subtitle1">Dose*</td> <td class="subtitle1">Adverse effects</td> </tr> <tr> <td class="subtitle2_left" colspan="4">First-line options</td> </tr> <tr> <td class="indent1">Ursodeoxycholic acid</td> <td>Choleretic</td> <td> <p>10 to 20 mg/kg/day orally, divided in 2 doses (maximum 300 mg twice daily)</p> An oral liquid formulation is not commercially available but may be prepared by a compounding pharmacy (usual concentration 60 mg/mL)</td> <td>Diarrhea, abdominal pain, worsening pruritus, or cholestasis at high dose</td> </tr> <tr> <td class="indent1">Diphenhydramine</td> <td>Antihistamine</td> <td> <p>5 mg/kg/day orally, divided in 3 or 4 doses (maximum 50 mg/dose)</p> Oral liquid concentration – 2.5 mg/mL</td> <td rowspan="2">Drowsiness, anticholinergic effects (eg, dry mouth, urinary hesitancy), impaired school performance</td> </tr> <tr> <td class="indent1">Hydroxyzine</td> <td>Antihistamine</td> <td> <p>2 mg/kg/day orally, divided in 3 or 4 doses (maximum 25 mg/dose)</p> Oral liquid concentration – 2 mg/mL</td> </tr> <tr> <td class="indent1">Rifampin (rifampicin)</td> <td>Antibiotic</td> <td> <p>Patients ≥4 months – 4 to 10 mg/kg/day orally, divided in 2 doses (maximum 600 mg/day)</p> <p>An oral liquid formulation is not commercially available but may be prepared by a compounding pharmacy</p> To deliver a dose of 150 or 300 mg, contents of a capsule may be mixed with applesauce, pudding, or other semisoft food</td> <td>Red discoloration of body fluids, nausea, decreased appetite, hypersensitivity reactions, hepatitis, and altered metabolism of other drugs via induction of cytochrome P450 3A</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Second-line options</td> </tr> <tr> <td class="indent1">Maralixibat<sup>¶</sup></td> <td>Ileal bile acid transport inhibitor</td> <td> <p>Patients ≥3 months – 190 micrograms/kg orally once daily for 7 days (maximum initial dose 14.25 mg/day) and then increased to 380 micrograms/kg daily (maximum dose 28.5 mg daily)</p> Available as 9.5 mg/mL oral solution</td> <td>Gastrointestinal symptoms, malabsorption (including fat-soluble vitamins), increased transaminases</td> </tr> <tr> <td class="indent1">Odevixibat<sup>Δ</sup></td> <td>Ileal bile acid transport inhibitor</td> <td>Patients ≥12 months – 120 micrograms/kg taken orally once daily</td> <td>Gastrointestinal symptoms, hematoma, and decreased weight</td> </tr> <tr> <td class="indent1">Naltrexone</td> <td>Opioid antagonist</td> <td> <p>0.25 to 0.5 mg/kg orally once daily (maximum 50 mg/dose); limited pediatric data</p> An oral liquid formulation is not commercially available but may be prepared by a compounding pharmacy</td> <td> <p>Self-limited opioid withdrawal-like syndrome can occur in patients not receiving opioids; elevated transaminases</p> Avoid use in patients receiving opioids (reverses analgesia, precipitates withdrawal)</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Third-line options</td> </tr> <tr> <td class="indent1">Sertraline</td> <td>Selective serotonin reuptake inhibitor</td> <td> <p>1 to 4 mg/kg/day orally (maximum 100 mg/day)</p> Oral concentrate – 20 mg/mL; measured dose must be further diluted with 4 ounces (120 mL) water, ginger ale, lemon/lime soda, lemonade, or orange juice</td> <td> <p>Behavior disorders, skin reactions, vomiting, transient arterial hypertension</p> <p>Do not use in patients with moderate or severe hepatic impairment</p> </td> </tr> <tr> <td class="indent1">Cholestyramine</td> <td>Bile-salt binding agent</td> <td> <p>240 mg/kg/day orally divided in 3 doses (maximum 8 g/day)</p> Measured dose of oral powder (resin) must be mixed with 60 to 180 mL of water or other noncarbonated beverage</td> <td rowspan="2"> <p>Constipation, abdominal pain, hyperchloremic metabolic acidosis, malabsorption (including fat-soluble vitamins)</p> Not to be taken at same time with many other medications, due to decreased absorption; refer to drug interactions program included with UpToDate</td> </tr> <tr> <td class="indent1">Colesevelam</td> <td>Bile-salt binding agent</td> <td> <p>Limited pediatric data</p> <p>Adult dose – 625 mg orally once daily; can titrate up to maximum 3.75 g daily in 1 or 2 divided doses</p> Available as granules for suspension (3.75 g per packet); measured dose must be mixed with 240 mL of water, fruit juice, or diet soda</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Other</td> </tr> <tr> <td class="indent1">Atorvastatin</td> <td>Lipid-lowering agent</td> <td> <p>Children and adolescents 10 to 17 years – 10 mg once daily; limited pediatric data</p> <p class="extra_spacing_top">Oral tablets may be crushed</p> <p class="extra_spacing_top">Available as 10 mg/2.5 mL oral suspension</p> </td> <td>Myalgias, myopathy, increased transaminases (usually transient, rarely hepatotoxic)</td> </tr> </tbody></table></div><div class="graphic_lgnd">This table lists medications doses used for treatment of cholestatic pruritus in Alagille syndrome. Dose adjustments may be needed based on level of symptoms, response, and adverse effects; combinations of medications are often required. For a stepwise approach to prescribing and regimen modifications based on factors including kidney or hepatic impairment and drug interactions, refer to UpToDate content on Alagille syndrome and Lexicomp drug monographs.</div><div class="graphic_footnotes"><p>FDA: US Food and Drug Administration.</p>
<p>* Commonly available concentrations (mg/mL) for commercially prepared oral liquids are listed. Other concentrations may be available. Consult Lexicomp drug reference and product labeling to confirm concentration of product dispensed.</p>
<p>¶  Maralixibat is approved by the FDA for treatment of cholestatic pruritus in people with Alagille syndrome ≥3 months of age.</p>
Δ Odevixibat is approved by the FDA for the treatment of cholestatic pruritus in people with Alagille syndrome ≥12 months of age.</div><div class="graphic_reference">Adapted from:
<ol>
<li>Kamath BM, Loomes KM, Piccoli DA. Medical management of Alagille syndrome. J Pediatr Gastroenterol Nutr 2010; 50:580.</li>
<li>Kohut TJ, Gilbert MA, Loomes KM. Alagille Syndrome: A Focused Review on Clinical Features, Genetics, and Treatment. Semin Liver Dis 2021; 41:525.</li>
</ol>
<p class="extra_spacing_top">Additional data from:</p>
<ol>
<li>Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</li>
</ol></div><div id="graphicVersion">Graphic 141283 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
